To explore the potential mechanism, we investigated the correlation between TMEM16A expression and mutation status of KRAS, NRAS, and BRAF, and the protein expression of most commonly used IHC Characteristics including BRAF (V600E), CDX2, EGFR, p53, Ki67, CD34, PMS2, MLH1, MSH6, and MSH2 in clinical CRC sample. This evidence concerns the gene CDX2 and colorectal carcinoma.